Incyte is trading at $122.50, up 4.18%, alongside broader strength in biotech and major U.S. indexes.
- Biotech ETF XBI is up 2.13%, and major U.S. indexes are also sharply higher.
- No clear company-specific catalyst was reported as directly driving the November 4 move.
- Incyte announced it will present more than 30 hematology abstracts at the December ASH meeting, including updated clinical data; available reporting does not link the announcement to the share-price rise.